Skip to main content
Back
Watch Compare

iBio, Inc.

Data quality: 100%
IBIO
Nasdaq Manufacturing Chemicals
$2.16
▼ $0.04 (-1.82%)
Mkt Cap: 76.51 M
Price
$2.22
Mkt Cap
76.51 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -35.91% annually over 5 years
Negative free cash flow of -19.19 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 113.69%
Capital intensive — 187.67% of revenue goes to capex

Growth

Revenue Growth (5Y)
-35.91%
Below sector avg (1.82%)
Revenue (1Y)77.78%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-43.94%
Above sector avg (-53.53%)
ROIC-34.52%
Net Margin-8245.67%
Op. Margin-8491.00%

Safety

Debt / Equity
N/A
Current Ratio9.04
Interest Coverage-145.56

Valuation

PE (TTM)
-3.09
Below sector avg (-1.48)
P/B Ratio1.35
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -3.1 -1.5
P/B 1.4 1.6
ROE % -43.9 -53.5
Net Margin % -8245.7 -41.5
Rev Growth 5Y % -35.9 1.8
D/E — 0.3

Analyst Price Target

6 analysts
Buy
Current
$2.16
+148.5%
Target
$5.37
$4.20
$5.00
$7.00
Forecast
Forward P/E -7.45
Forward EPS -$0.29
Est. Revenue 120,000.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.29
-$0.39 – -$0.19
 120,000.0 5
FY2026 -$0.31
-$0.35 – -$0.27
 180,000.0 6

Earnings Surprises

Last 6 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.07 -$0.09 -38.5%
Q32025 -$0.07 -$0.11 -50.0%
Q22025 -$0.37 -$0.32 +12.3%
2026-Q2 -$0.06 -$0.08 -29.7%
2026-Q1 -$0.06 -$0.11 -73.8%
Q12025 -$0.32 -$0.49 -53.1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 77.78% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -35.91% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 300,000.0 Net Income (TTM) -24.74 M
ROE -43.94% ROA -38.49%
Gross Margin N/A Operating Margin -8491.00%
Net Margin -8245.67% Free Cash Flow (TTM) -19.19 M
ROIC -34.52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 9.04
Interest Coverage -145.56 Asset Turnover 0.00
Working Capital 47.47 M Tangible Book Value 52.22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.09 Forward P/E N/A
P/B Ratio 1.35 P/S Ratio 255.05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -25.08%
Market Cap 76.51 M Enterprise Value 47.84 M
Per Share
EPS (Diluted TTM) -1.00 Revenue / Share 0.01
FCF / Share -0.56 OCF / Share -0.54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 187.67% FCF Conversion 77.57%
SBC-Adj. FCF -20.55 M Growth Momentum 113.69

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 400,000.0 225,000.0 0.0 2.38 M 2.37 M
Net Income -18.38 M -24.91 M -65.01 M -50.30 M -23.21 M
EPS (Diluted) -1.75 -6.50 -5.31 -5.78 —
Gross Profit — — — 2.17 M 909,000.0
Operating Income -18.60 M -16.63 M -29.34 M -49.69 M -31.11 M
EBITDA — — — — —
R&D Expenses 8.31 M 5.19 M 10.33 M 17.73 M 9.99 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 212,000.0 172,000.0 83,000.0 1.41 M 2.45 M
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 23.19 M 28.73 M 41.21 M 99.41 M 146.97 M
Total Liabilities 8.31 M 7.41 M 25.83 M 35.92 M 38.40 M
Shareholders' Equity 14.88 M 21.32 M 15.38 M 63.49 M 108.59 M
Total Debt — — — — —
Cash & Equivalents 8.58 M 14.21 M 4.30 M 22.68 M 77.40 M
Current Assets 9.72 M 15.67 M 26.26 M 45.07 M 104.60 M
Current Liabilities 6.11 M 3.84 M 21.58 M 30.44 M 6.65 M